Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

CD52 expression in hairy cell leukemia.

Michael M Quigley¹, Kelly J Bethel, Robert W Sharpe

¹Division of Hematopathology, Scripps Clinic Laboratories, Scripps Clinic, La Jolla, California 92037, USA. mmquigley@nmcsds.med.navy.mil

American Journal of Hematology

|November 25, 2003

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Low-Dose Vemurafenib Plus Rituximab in Front-Line and Relapsed or Refractory Hairy Cell Leukemia: The Scripps Regimen.

Blood advances·2026

Same author

A novel JAK1 variant in chronic eosinophilic leukaemia with response to benralizumab.

British journal of haematology·2026

Same author

Updated consensus guidelines for the diagnosis and management of patients with HCL and HCL variant.

Blood·2026

Same author

Expert consensus opinion on the management of hairy cell leukemia in elderly patients.

Leukemia & lymphoma·2025

Same author

IgG3κ Monoclonal Membranous Nephropathy Associated With Acquired Lecithin Cholesterol Acyltransferase Deficiency.

American journal of kidney diseases : the official journal of the National Kidney Foundation·2025

Same author

Threading through the data for chemotherapy-free alternatives in the treatment of hairy cell leukemia.

Leukemia & lymphoma·2025

Same journal

EIF2AK1 As a Key Genetic Determinant of Luspatercept Resistance in Transfusion-Dependent Thalassemia.

American journal of hematology·2026

Same journal

Subtotal Versus Total Splenectomy in Children With Sickle Cell Disease: Clinical Outcomes and Splenic Function Assessed by Pocked Red Blood Cell Count.

American journal of hematology·2026

Same journal

High Proportion of PNH Type II Neutrophils Is Associated With Thrombosis in Patients Displaying a PNH Clone ≥ 1.

American journal of hematology·2026

Same journal

Peripheral Blood Lymphocytosis Reflecting an Underlying Thymoma.

American journal of hematology·2026

Same journal

Undetectable Hydroxyurea Levels in the Majority of Sickle Cell Disease Patients, Especially in Young Children.

American journal of hematology·2026

Same journal

Myelodysplastic Syndromes: 2026 Update on Diagnosis, Risk-Stratification and Management.

American journal of hematology·2026

See all related articles

Hairy cell leukemia (HCL) is a rare B-cell cancer. This study found that HCL cells express CD52, supporting the use of alemtuzumab (anti-CD52) for treating refractory HCL cases.

Area of Science:

Hematology
Immunology
Oncology

Background:

Hairy cell leukemia (HCL) is a rare chronic B-cell lymphoproliferative disorder.
Refractory HCL cases have limited treatment alternatives.
Monoclonal antibody therapy, such as alemtuzumab (anti-CD52), shows promise for B-cell malignancies.

Purpose of the Study:

To investigate CD52 antigen expression on malignant cells in HCL.
To determine the rationale for using alemtuzumab in refractory HCL.

Main Methods:

Flow cytometry was used to analyze CD52 expression.
Nine cases of HCL and one HCL variant were examined.

Main Results:

All examined HCL cases showed high expression of CD52 antigen (92-100%) on malignant cells.

Related Experiment Videos

CD52 expression was consistently demonstrated on HCL cells.

Conclusions:

The consistent CD52 antigen expression on HCL cells provides a strong rationale for alemtuzumab therapy.
Alemtuzumab is a potential treatment option for patients with refractory HCL.